类风湿关节炎生物及靶向药物的严重不良事件风险:系统综述与Meta分析
该系统综述纳入117项随机试验(47 615例患者),采用网络Meta分析比较10种已获批生物及靶向合成DMARDs的严重不良事件(SAE)和死亡风险。结果显示,certolizumab的SAE发生率高于abatacept、adalimumab、etanercept、golimumab、rituximab、tofacitinib及对照;tocilizumab高于abatacept、etanercept和rituximab。各药物与对照间死亡率无差异;因缺乏头对头试验及间接估计不精确,GRADE证据置信度低。
要点
- certolizumab的SAE发生率高于abatacept、adalimumab、etanercept、golimumab、rituximab、tofacitinib及对照。
- tocilizumab的SAE发生率高于abatacept、etanercept和rituximab。
- 各b/ts-DMARDs与对照间死亡率无差异,GRADE证据置信度低。
核心结论
- 尽管证据置信度低,分析发现10种b/ts-DMARDs间SAE发生率可能存在差异,选择药物时需谨慎。
研究设计与样本
- 系统综述检索文献数据库、试验注册库及监管机构网站,纳入已获批b/ts-DMARDs治疗RA的随机试验。
- 采用混合效应泊松回归模型进行网络Meta分析,基于事件发生与暴露人年计算SAE和死亡的率比。
- 共纳入117项试验、47 615例患者,采用GRADE方法评估估计值置信度。
主要发现
- certolizumab相比abatacept的SAE率比为1.58(95% CI:1.18,2.14),相比adalimumab为1.36(95% CI:1.02,1.81)。
- certolizumab相比etanercept的SAE率比为1.60(95% CI:1.18,2.17),相比golimumab为1.45(95% CI:1.00,2.08)。
- certolizumab相比rituximab的SAE率比为1.63(95% CI:1.16,2.30),相比tofacitinib为1.44(95% CI:1.03,2.02),相比对照为1.45(95% CI:1.13,1.87)。
- tocilizumab相比abatacept的SAE率比为1.30(95% CI:1.03,1.65),相比etanercept为1.31(95% CI:1.04,1.67),相比rituximab为1.34(95% CI:1.01,1.78)。
- 其他比较无统计学显著性;考虑研究持续时间后,上述发现在治疗≤6个月时得到确认,但在6–24个月时未得到确认;各b/ts-DMARDs与对照间死亡率无差异。
关键数值与推荐
- SAE率比基于受试者事件发生与暴露人年计算,采用混合效应泊松回归模型。
- GRADE评估因缺乏头对头比较试验和间接估计不精确,置信度低。
临床怎么用
- 在缺乏头对头试验的情况下,临床选择b/ts-DMARDs时可参考上述SAE率比差异,对certolizumab和tocilizumab的SAE风险保持警惕。
- 因证据置信度低且长期(6–24个月)结果不一致,上述差异应结合患者个体情况谨慎解读。
局限性
- 缺乏头对头比较试验,间接估计不精确,GRADE证据置信度低。
- 考虑研究持续时间后,SAE差异在6–24个月治疗中未得到确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine possible differences in serious adverse effects among the 10 currently approved biological and targeted synthetic DMARDs (b/ts-DMARDs) for RA. METHODS: Systematic review in bibliographic databases, trial registries and websites of regulatory agencies identified randomized trials of approved b/ts-DMARDs for RA. Network meta-analyses using mixed-effects Poisson regression models were conducted to calculate rate ratios for serious adverse events (SAEs) and deaths between each of the 10 drugs and control (i.e. no b/ts-DMARD treatment), based on subjects experiencing an event in relation to person-years. Confidence in the estimates was assessed by applying the Grading of Recommendations Assessment, Development and Evaluation approach (GRADE). RESULTS: A total of 117 trials (47 615 patients) were included. SAEs were more common with certolizumab compared with abatacept (rate ratio = 1.58, 95% CI: 1.18, 2.14), adalimumab (1.36, 95% CI: 1.02, 1.81), etanercept (1.60, 95% CI: 1.18, 2.17), golimumab (1.45, 95% CI: 1.00, 2.08), rituximab (1.63, 95% CI: 1.16, 2.30), tofacitinib (1.44, 95% CI: 1.03, 2.02) and control (1.45, 95% CI: 1.13, 1.87); and tocilizumab compared with abatacept (1.30, 95% CI: 1.03, 1.65), etanercept (1.31, 95% CI: 1.04, 1.67) and rituximab (1.34, 95% CI: 1.01, 1.78). No other comparisons were statistically significant. Accounting for study duration confirmed our findings for up to 6 months' treatment but not for longer-term treatment (6-24 months). No differences in mortality between b/ts-DMARDs and control were found. Based on the GRADE approach, confidence in the estimates was low due to lack of head-to-head comparison trials and imprecision in indirect estimates. CONCLUSION: Despite low confidence in the estimates, our analysis found potential differences in rates of SAEs. Our data suggest caution should be taken when deciding among available drugs. SYSTEMATIC REVIEW REGISTRATION NUMBER: PROSPERO CRD42014014842.
引用
- Tarp S, Eric Furst D, Boers M, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford). 2017. PMID: 28013201. doi:10.1093/rheumatology/kew442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。